The Centers for Medicare & Medicaid Services announced that enforcement actions have stopped more than $1.6 billion in potentially improper Medicare laboratory payments since the Trump administration began.
The agency said the savings include $732 million from revoking 157 fraudulent lab providers from the Medicare program. Additional savings came from $500 million in potentially fraudulent payments halted through 185 payment suspensions from CMS' investigation of 600 labs, more than $276 million recouped from 442 identified overpayments, and $127 million in payments prevented through 85 law enforcement referrals.
CMS used advanced analytics, including artificial intelligence and machine-learning models, to identify potential fraud by analyzing Medicare fee-for-service claims for unusual billing patterns. The agency said the technology helped identify laboratory fraud by detecting unusual combinations of testing, results, billing, documentation, and relationships that may indicate manipulation or fraudulent activity.
The agency targeted multiple types of lab fraud, including billing for medically unnecessary services to beneficiaries without established relationships with ordering providers, billing for services not rendered, and billing for upcoded services. Fraudulent patterns occurred across pathogen detection, high-complexity drug tests, and genetic testing.
According to CMS, one individual owned a consulting company that enrolled 14 labs in Medicare and billed more than $24 million for services that could not have been rendered because none of the labs were found to be operational. CMS said it had suspended $12 million of the labs' payments and recouped an additional $7 million, with the revocation of 11 of the 14 labs' Medicare enrollments.
Another case involved a Texas lab that began billing in late February 2026 and received minimal payment before CMS detected suspicious activity. The agency said it denied $1.2 million of the laboratory's claims, and after the lab shifted billing practices in early April, a payment suspension prevented more than $150,000 in additional suspect payments. The provider was revoked that same month.
A third Texas lab that began billing earnestly in May 2026 had $1.9 million in claims denied and $1.7 million captured by payment suspension, according to CMS.